A drug patent can be owned on paperyet effectively controlled by someone else.
Thats the uncomfortable reality DrugPatentWatch highlights in its latest piece: when a new owner fails to file the patent assignment properly, the chain of control can fract…
The New Owner Didn’t File the Patent. Here’s Who Actually Controls It. Read Post »
Zero for Two: Why No Antibody-Drug Conjugate Has Ever Faced a Biosimilar
For investors, the biosimilar story has been one of the most reliable value creation engines in healthcareuntil you look at antibody-drug conjugates.
So far, the scorecard is zero…
Zero for Two: Why No Antibody-Drug Conjugate Has Ever Faced a Biosimilar Read Post »
CRISPR was supposed to be protected by platform patents. Fourteen years later, the litigation story says: not really.
For years, the gene-editing industry has operated on a kind of legal common sense: broad, platform patents would establish stable grou…
Stop Tracking Drug Patents. Start Tracking Who Controls Them.
Drug patent analytics used to be a clean story: list the patents, map the expirations, forecast generic entry. It was orderlyalmost spreadsheet-predictable. But the market doesnt move in str…
Stop Tracking Drug Patents. Start Tracking Who Controls Them. Read Post »
Google Patents wasnt built for pharma. Heres what it misses every time you search a drug name.
Pharma teams dont Google patentsthey interrogate them.
Yet the moment you type a molecule, a brand name, or an ingredient into Google Patents, youre likely g…
ð¨ The three-week bottleneck isnt a workload problemits a process problem.
In an era when drug approvals, reimbursement decisions, and competitive launches move at the speed of data, waiting three weeks for an analyst report that should have taken …
Your competitive intelligence team is still reading PACER by hand. Heres the cost in reaction time.
In the pharma and life sciences world, speed isnt just a nice to have. Its a competitive moat.
If your competitive intelligence team is still pulling do…
Strong IP Doesnt Win in CourtEnforceable IP Does
In pharma, its easy to confuse strength with survivability.
Companies invest years building patent wallslayering claims, stacking continuations, expanding coverage, and betting big on courtroom outcomes….
Strong IP Doesn’t Win in Court. Enforceable IP Does. Read Post »
Stop Calling It Loss of Exclusivity for Most DrugsIts Loss of Pricing Power, Not Revenue
For years, the industry has repeated a soothing phrase: loss of exclusivity. It sounds clinical, inevitable, almost benignlike a patent clock running out and nothi…
The Patent Cliff Isnt a CliffIts a Negotiation. And Authorized Generics Are the Stealth Lever.
The market loves a clean story: patents expire, generics rush in, prices fall, and everyone moves on. But in branded pharmaceuticals, the reality is messiera…
The Authorized Generic That Beats the Patent Cliff to Market Read Post »